How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease

被引：0
|
作者：
Fujioka, Hayato [1 ]
Kataoka, Naoya [1 ]
Imamura, Teruhiko [1 ]
机构：
[1] Univ Toyama, Dept Internal Med 2, Toyama, Japan
来源：
INTERNAL MEDICINE | 2024年 / 63卷 / 15期
关键词：
uric acid; SGLT2; inhibitor; cardiovascular disease; heart failure;
D O I：
10.2169/internalmedicine.2725-23
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2227 / 2227
页数：1
相关论文
共 50 条
  • [1] The Authors' Reply to "How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease"
    Mori, Daisuke
    Kobayashi, Midori
    Wada, Masafumi
    Tokuchi, Maho
    Misegawa, Soichiro
    Saito, Rina
    Nomi, Hiroki
    Haga, Ryota
    Nagatoya, Katsuyuki
    Yamauchi, Atsushi
    INTERNAL MEDICINE, 2024, 63 (15) : 2229 - 2230
  • [2] Dapagliflozin in Patients with Chronic Kidney Disease
    Heerspink, Hiddo J. L.
    Stefansson, Bergur V.
    Correa-Rotter, Ricardo
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan-Fan
    Mann, Johannes F. E.
    McMurray, John J. V.
    Lindberg, Magnus
    Rossing, Peter
    Sjostrom, C. David
    Toto, Roberto D.
    Langkilde, Anna-Maria
    Wheeler, David C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15): : 1436 - 1446
  • [3] New Impact of Hyperuricemia and Chronic Kidney Disease for the Patients with Carotid Endarterectomy
    Sayama, T.
    Shimogaw, T.
    Hamamura, T.
    Morioka, T.
    CEREBROVASCULAR DISEASES, 2013, 36 : 70 - 71
  • [4] Dapagliflozin in Patients with Chronic Kidney Disease REPLY
    Heerspink, Hiddo J. L.
    Langkilde, Anna-Maria
    Wheeler, David C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (04): : 389 - 390
  • [5] Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease
    Hitoshi Nishizawa
    Norikazu Maeda
    Iichiro Shimomura
    Hypertension Research, 2022, 45 : 635 - 640
  • [6] Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease
    Nishizawa, Hitoshi
    Maeda, Norikazu
    Shimomura, Iichiro
    HYPERTENSION RESEARCH, 2022, 45 (04) : 635 - 640
  • [7] Dapagliflozin for rheumatic musculoskeletal disease in patients with chronic kidney disease
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Akiyama, Mitsuhiro
    Saito, Shutaro
    Kondo, Yasushi
    Azegami, Tatsuhiko
    Kaneko, Yuko
    MODERN RHEUMATOLOGY, 2024,
  • [8] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
    Patoulias, Dimitrios
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (07)
  • [9] Dapagliflozin versus empagliflozin in patients with chronic kidney disease
    Alnsasra, Hilmi
    Tsaban, Gal
    Solomon, Adam
    Khalil, Fouad
    Aboalhasan, Enis
    Azab, Abed N.
    Azuri, Joseph
    Hammerman, Ariel
    Arbel, Ronen
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA
    Khimion, L.
    Naishtetik, I.
    Burianov, O.
    Rotova, S.
    Smiyan, S.
    Danyliuk, S.
    Trofanchuk, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1652 - 1652
12345